openPR Logo
Press release

Insulin Biosimilars Industry to Witness Massive Growth (2024-2031) | Pfizer Inc., Biocon, Inc., MERCK & CO., Eli Lilly & Co., NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG

07-10-2024 11:13 AM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Insulin Biosimilars Industry to Witness Massive Growth

DataM Intelligence has published a new research report on "Insulin Biosimilars Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/insulin-biosimilars-market

The Insulin Biosimilars market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.

Insulin Biosimilars refer to biologic medical products that are highly similar to already approved reference insulin products, with no clinically meaningful differences in terms of safety, purity, and potency. These biosimilars are designed to provide the same therapeutic effects as their original branded counterparts, offering an alternative treatment option for diabetes patients who require insulin to manage their blood glucose levels.

Forecast Growth Projected:

The Global Insulin Biosimilars Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

List of the Key Players in the Insulin Biosimilars Market:

Pfizer Inc., Biocon, Inc., MERCK & CO., Eli Lilly & Co., NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG, Amphastar Pharmaceuticals, Inc., Julphar Gulf Pharmaceutical Industries

Segment Covered in the Insulin Biosimilars Market:

By Product: Long Acting Biosimilars, Rapid Acting Biosimilars, Premixed Biosimilars

By Indication: Type 1 Diabetes, Type 2 Diabetes

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis:

The global Insulin Biosimilars Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/insulin-biosimilars-market

Regional Analysis:

The global Insulin Biosimilars Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Insulin Biosimilars Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Insulin Biosimilars manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Insulin Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get a Free Sample PDF copy of the report @ https://datamintelligence.com/download-sample/insulin-biosimilars-market

Read Latest Blog: https://www.datamintelligence.com/blogs/top-10-process-automation-companies-worldwide

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insulin Biosimilars Industry to Witness Massive Growth (2024-2031) | Pfizer Inc., Biocon, Inc., MERCK & CO., Eli Lilly & Co., NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG here

News-ID: 3574065 • Views:

More Releases from DataM intelligence 4 Market Research LLP

United States Legal AI Software Market to Reach USD 3.7 Billion by 2030, Driven by Automation and Efficiency Demands | DataM Intelligence
United States Legal AI Software Market to Reach USD 3.7 Billion by 2030, Driven …
The global Legal AI Software Market reached USD 0.5 billion in 2022 and is projected to reach USD 3.7 billion by 2030, growing at a CAGR of 28.7% during the forecast period 2024-2031, according to DataM Intelligence. United States: Recent Industry Developments ✅ In September 2025, Thomson Reuters launched its next-generation AI contract review platform, reducing document analysis time by 80% for corporate legal teams. ✅ In August 2025, A coalition of top
United States AI In Renewable Energy Market to Reach USD 4.85 Billion by 2032, Driven by Grid Optimization and Predictive Maintenance | DataM Intelligence
United States AI In Renewable Energy Market to Reach USD 4.85 Billion by 2032, D …
The global AI In Renewable Energy Market reached US$ 0.85 billion in 2024 and is projected to reach US$ 4.85 billion by 2032, growing at a CAGR of 24.32% during the forecast period 2025-2032, according to DataM Intelligence. United States: Recent Industry Developments ✅ In September 2025, The National Renewable Energy Laboratory (NREL) launched an AI platform that improved solar generation forecasts by 30%, significantly enhancing grid reliability. ✅ In August 2025,
United States AI In Energy Market Projected to Expand at 33.45% CAGR, Reaching US$ 99.48 billion by 2032 | DataM Intelligence
United States AI In Energy Market Projected to Expand at 33.45% CAGR, Reaching U …
The global AI In Energy Market reached US$ 9.89 billion in 2024 and is projected to reach US$ 99.48 billion by 2032, growing at a CAGR of 33.45% during the forecast period 2025-2032, according to DataM Intelligence. United States: Recent Industry Developments ✅ In September 2025, Google DeepMind partnered with a major US utility to implement AI for real-time grid optimization, reducing energy losses by 15%. ✅ In
United States Allergy Immunotherapies Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities
United States Allergy Immunotherapies Market 2025 | Growth Drivers, Trends & Mar …
Market Size and Growth The "Global Allergy Immunotherapies Market" is predicted to reach at a high CAGR of 10.4% during the forecast period (2022-2029) Key Development: United States: Recent Industry Developments ✅ In September 2025, Sanofi expanded its allergy immunotherapy portfolio by acquiring Ayvakit and early-stage immunology assets for USD 9.1 billion, enhancing its position in severe allergic conditions. ✅ In June 2025, BioVaxys Technology Corp. launched a private placement to raise USD 1.2-1.6

All 5 Releases


More Releases for Biosimilars

Transformative Trends Impacting the Biosimilars Market Landscape: Innovative Pro …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Biosimilars Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The dimensions of the biosimilars market have been rapidly expanding over the last couple of years. The escalation, from a worth of $18.65 billion in 2024 to an estimated value of $21.95 billion in 2025, denotes
Evolving Market Trends In The Biosimilars Industry: Innovative Product Launched …
The Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Biosimilars Market Size During the Forecast Period? The dimension of the biosimilars market has experienced substantial expansion in the last few years. The market value, which was at $18.65 billion in 2024,
Prominent Rituximab Biosimilars Market Trend for 2025: Collaborative Innovations …
Which drivers are expected to have the greatest impact on the over the rituximab biosimilars market's growth? The rituximab biosimilars market is anticipated to grow due to the projected increase in non-Hodgkin's lymphoma (NHL) cases. NHL is a cancer that originates in the white blood cells and lymphocytes, which are integral parts of the body's immune system. For example, the American Cancer Society, a cancer advocacy group based in the US,
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million